FDA Panel Backs Collegium's 'Abuse-Deterrent' Painkiller
A U.S. Food and Drug Administration panel on Friday voted in support of Collegium Pharmaceutical Inc.'s opioid painkiller product meant to address severe pain that requires "daily, around-the-clock, long-term" treatment, and which...To view the full article, register now.
Already a subscriber? Click here to view full article